



PTO/SB/08a/b (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/602,544
				Filing Date	June 23, 2003
				First Named Inventor	Li-Fang Liang
				Art Unit	1632
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	MTN-027DV1CN

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/SL/	A1	5,665,543	09-09-1997	Foulkes, <i>et al.</i>	
/SL/	A2	5,827,733	10-27-1998	Lee, <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
/SL/	A3	WO 97/11190 A2, A3	03-27-1997	Paradigm Biosciences Inc.		
/SL/	A4	WO 00/01810 A1	01-13-2000	New Zealand Pastoral Agriculture Research Institute, Ltd.		
/SL/	A5	CA 2332555	01-13-2000	Bass, J., <i>et al.</i>		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>2</sup>
/SL/	A6	Cameron, E.R. "Recent advances in transgenic technology." <i>Mol Biotechnol.</i> 1997 Jun; 7(3):253-65.				
	A7	Crystal, R.G. "Transfer of genes to humans: early lessons and obstacles to success." <i>Science.</i> 1995 Oct 20; 270(5235):404-10.				
	A8	Deonarain, M.P. "Ligand-targeted receptor-mediated vectors for gene delivery." <i>Exp. Opin. Ther. Patents.</i> 1998; 8(1):53-69.				
	A9	Dickman, S. "Gene mutation provides more meat on the hoof." <i>Science.</i> 1997 Sep 26; 277(5334):1922-3.				
	A10	Eck, <i>et al.</i> "Gene based therapy." Goodman & Gilman's <u>The Pharmacological Basis of Therapeutics</u> , 9 <sup>th</sup> Edition, Chapter 5, pp. 77-101.				
	A11	Ferrell, R.E., <i>et al.</i> "Frequent sequence variation in the human myostatin (GDF8) gene as a marker for analysis of muscle-related phenotypes." <i>Genomics.</i> 1999 Dec 1; 62(2):203-7.				
	A12	GenBank Accession Number AJ133580 for <i>Sus scrofa</i> partial myostation gene.				
	A13	GenBank Accession Number AF093798 for <i>Sus scrofa</i> myostatin (gdf8) gene.				
	A14	GenBank Accession Number X24464 for Bovine myostatin genomic DNA.				

Examiner Signature	/Scott Long/	Date Considered	05/29/2007
--------------------	--------------	-----------------	------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE  STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/602,544
				Filing Date	June 23, 2003
				First Named Inventor	Li-Fang Liang
				Art Unit	1632
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	MTN-027DV1CN

/SL/	B1	Gonzalez-Cadavid, N.F., <i>et al.</i> "Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting." <i>Proc Natl Acad Sci USA</i> . 1998 Dec 8; 95(25):14938-43.	
	B2	Grobet, L., <i>et al.</i> "A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle." <i>Nat Genet</i> . 1997 Sep; 17(1):71-4.	
	B3	Grobet, L., <i>et al.</i> "Molecular definition of an allelic series of mutations disrupting the myostatin function and causing double-muscling in cattle." <i>Mamm Genome</i> . 1998 Mar; 9(3):210-3.	
	B4	Ji, S., <i>et al.</i> "Myostatin expression in porcine tissues: tissue specificity and developmental and postnatal regulation." <i>Am J Physiol</i> . 1998 Oct; 275(4 Pt 2):R1265-73.	
	B5	Kambadur, R., <i>et al.</i> "Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle." <i>Genome Res</i> . 1997 Sep; 7(9):910-6.	
	B6	McPherron, A.C., <i>et al.</i> "GDF-3 and GDF-9: two new members of the transforming growth factor-beta superfamily containing a novel pattern of cysteines." <i>J Biol Chem</i> . 1993 Feb 15; 268(5):3444-9.	
	B7	McPherron, A.C., <i>et al.</i> "Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member." <i>Nature</i> . 1997 May 1; 387(6628):83-90.	
	B8	McPherron, A.C., <i>et al.</i> "Double muscling in cattle due to mutations in the myostatin gene." <i>Proc Natl Acad Sci USA</i> . 1997 Nov 11; 94(23):12457-61.	
	B9	Miller, N., <i>et al.</i> "Targeted vectors for gene therapy." <i>FASEB J</i> . 1995 Feb; 9(2):190-9.	
	B10	Mullins, <i>et al.</i> "Perspectives series: Molecular medicine in genetically engineered animals." <i>J. Clin. Invest</i> . 98(11):S37-40.	
	B11	Murch, S.H., <i>et al.</i> "Nutrition in inflammatory bowel disease." <i>Baillieres Clin Gastroenterol</i> . 1998 Dec; 12(4):719-38.	
	B12	Palmiter, R.D., <i>et al.</i> "Germ-line transformation of mice." <i>Annu Rev Genet</i> . 1986; 20:465-99.	
	B13	Slack, J.M. "Growth control: action mouse." <i>Curr Biol</i> . 1997 Aug 1; 7(8):R467-9.	
	B14	Smith, T.P., <i>et al.</i> "Myostatin maps to the interval containing the bovine mh locus." <i>Mamm Genome</i> . 1997 Oct; 8(10):742-4.	
	B15	Sonstegard, T.S., <i>et al.</i> "Refinement of bovine chromosome 2 linkage map near the mh locus reveals rearrangements between the bovine and human genomes." <i>Anim Genet</i> . 1998 Oct; 29(5):341-7.	
	B16	Sonstegard, T.S., <i>et al.</i> "Myostatin maps to porcine chromosome 15 by linkage and physical analyses." <i>Anim Genet</i> . 1998 Feb; 29(1):19-22.	
	B17	Szabo, G., <i>et al.</i> "A deletion in the myostatin gene causes the compact (Cmpt) hypermuscular mutation in mice." <i>Mamm Genome</i> . 1998 Aug; 9(8):671-2.	
✓	B18	Verma, I.M., <i>et al.</i> "Gene therapy -- promises, problems and prospects." <i>Nature</i> . 1997 Sep 18; 389(6648):239-42.	
	B19	Westhusin, M. "From mighty mice to mighty cows." <i>Nat Genet</i> . 1997 Sep; 17(1):4-5.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Applicant's unique citation designation number (optional). \*Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Scott Long/	Date Considered	05/29/2007
--------------------	--------------	-----------------	------------